Disease Control and Prevention Center/Travel Clinic, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.
Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
BMC Infect Dis. 2024 Oct 24;24(1):1197. doi: 10.1186/s12879-024-10090-z.
Dexamethasone is currently administered for Coronavirus disease 2019(COVID-19); however, there are concerns about its effect on specific antibodies' production. The aim of this study was to evaluate whether specific antibodies were affected by COVID-19 severity and corticosteroid treatment.
Of 251 confirmed COVID-19 patients admitted to our hospital between January 26 and August 10, 2020, the early period of the pandemic, 75 patients with sera within 1 month of onset and 1 month or longer were included in the research. A total of 253 serum samples from these patients were collected. The levels of specific antibodies for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), immunoglobulin G (IgG) and M (IgM), were measured retrospectively. The results were compared separately of each COVID-19 severity, and with or without corticosteroid treatment.
Among the 75 patients, 47, 18, and 10 had mild, moderate, and severe disease, respectively. The median age was 53.0 years and 22 (29%) were women. The most common comorbidities were hypertension and dyslipidemia. Corticosteroids were administered to 20 (27%) and 10 (53%), patients with moderate and severe disease, respectively. The positivity rates IgM increased first, and IgG was almost always positive after day 16, regardless of the severity of COVID-19. On days 6-10, both IgG and IgM positivity rates were higher in patients with moderate disease than in those with mild or severe disease. In patients with moderate disease, IgG positivity was similar over time, regardless of corticosteroid treatment.
In COVID-19 patients, specific IgG is positive and maintained for a long period of time, even after corticosteroid treatment. The effect of corticosteroid treatment in a COVID-19 epidemiological study using specific IgG antibodies was considered minor. COVID-19 patients were more likely to receive oxygen if IgM was positive 1 week after onset, but not mechanical ventilation. IgM measurement 1 week after onset may predict COVID-19 severity.
地塞米松目前被用于治疗 2019 年冠状病毒病(COVID-19);然而,人们对其对特定抗体产生的影响存在担忧。本研究旨在评估 COVID-19 严重程度和皮质类固醇治疗是否会影响特定抗体。
在 2020 年 1 月 26 日至 8 月 10 日期间,我们医院收治的 251 例确诊的 COVID-19 患者中,纳入了病程早期(发病后 1 个月内)和病程超过 1 个月的 75 例患者。共采集这些患者的 253 份血清样本。回顾性测量严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)、免疫球蛋白 G(IgG)和 M(IgM)的特异性抗体水平。分别比较 COVID-19 严重程度、皮质类固醇治疗与无皮质类固醇治疗的结果。
在 75 例患者中,分别有 47 例、18 例和 10 例患者患有轻症、中症和重症疾病。中位年龄为 53.0 岁,22 例(29%)为女性。最常见的合并症为高血压和血脂异常。皮质类固醇分别用于 20 例(27%)和 10 例(53%)中症和重症患者。无论 COVID-19 严重程度如何,IgM 的阳性率均首先升高,IgG 在第 16 天后几乎总是呈阳性。在第 6-10 天,中症患者的 IgG 和 IgM 阳性率均高于轻症或重症患者。在中症患者中,无论皮质类固醇治疗与否,IgG 的阳性率随时间推移均相似。
在 COVID-19 患者中,特异性 IgG 呈阳性并持续很长时间,即使在皮质类固醇治疗后也是如此。使用特异性 IgG 抗体的 COVID-19 流行病学研究中,皮质类固醇治疗的效果被认为较小。如果 IgM 在发病后 1 周呈阳性,COVID-19 患者更有可能接受吸氧,但不是机械通气。发病后 1 周时 IgM 的测量可能预测 COVID-19 的严重程度。